Your browser doesn't support javascript.
loading
Isoalantolactone mediates the degradation of BCR-ABL protein in imatinib-resistant CML cells by down-regulating survivin.
Yin, Shan-Shan; Chen, Chen; Liu, Zhen; Liu, Shan-Ling; Guo, Jia-Hui; Zhang, Chao; Zhang, Quan-Wu; Gao, Feng-Hou.
Afiliación
  • Yin SS; Department of Oncology, Shanghai 9th People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Chen C; Clinical Pharmacology Research Center, Peking Union Medical College Hospital, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Chinese Academy
  • Liu Z; Department of Oncology, Shanghai 9th People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Liu SL; Department of Clinical Laboratory, The First Hospital of Changsha City, Changsha, China.
  • Guo JH; Department of Oncology, Shanghai 9th People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Zhang C; Department of Geriatrics, Shanghai ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Zhang QW; Department of Pathology, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, China.
  • Gao FH; Department of Oncology, Shanghai 9th People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Cell Cycle ; 22(12): 1407-1420, 2023 06.
Article en En | MEDLINE | ID: mdl-37202916
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Leucemia Mielógena Crónica BCR-ABL Positiva / Resistencia a Antineoplásicos Límite: Humans Idioma: En Revista: Cell Cycle Año: 2023 Tipo del documento: Article País de afiliación: China
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Leucemia Mielógena Crónica BCR-ABL Positiva / Resistencia a Antineoplásicos Límite: Humans Idioma: En Revista: Cell Cycle Año: 2023 Tipo del documento: Article País de afiliación: China